Format

Send to

Choose Destination
World J Stem Cells. 2019 Feb 26;11(2):55-72. doi: 10.4252/wjsc.v11.i2.55.

Rational use of mesenchymal stem cells in the treatment of autism spectrum disorders.

Author information

1
Department of Surgery, The Chinese University of Hong Kong, Hong Kong, China.
2
School of Rehabilitation, Kunming Medical University, Kunming 650500, Yunnan Province, China.
3
Department of Psychology, Weifang Medical University, Weifang 261053, Shandong Province, China.
4
Medical Sciences Division, University of Oxford, Oxford OX3 9DU, United Kingdom.
5
Mental Health Institute of the Second Xiangya Hospital, Central South University, Changsha 410011, Hunan Province, China.
6
Department of Psychiatry, the University of Hong Kong, Hong Kong, China. liqihku@gmail.com.
7
Department of Psychiatry, the University of Hong Kong, Hong Kong, China.

Abstract

Autism and autism spectrum disorders (ASD) refer to a range of conditions characterized by impaired social and communication skills and repetitive behaviors caused by different combinations of genetic and environmental influences. Although the pathophysiology underlying ASD is still unclear, recent evidence suggests that immune dysregulation and neuroinflammation play a role in the etiology of ASD. In particular, there is direct evidence supporting a role for maternal immune activation during prenatal life in neurodevelopmental conditions. Currently, the available options of behavioral therapies and pharmacological and supportive nutritional treatments in ASD are only symptomatic. Given the disturbing rise in the incidence of ASD, and the fact that there is no effective pharmacological therapy for ASD, there is an urgent need for new therapeutic options. Mesenchymal stem cells (MSCs) possess immunomodulatory properties that make them relevant to several diseases associated with inflammation and tissue damage. The paracrine regenerative mechanisms of MSCs are also suggested to be therapeutically beneficial for ASD. Thus the underlying pathology in ASD, including immune system dysregulation and inflammation, represent potential targets for MSC therapy. This review will focus on immune dysfunction in the pathogenesis of ASD and will further discuss the therapeutic potential for MSCs in mediating ASD-related immunological disorders.

KEYWORDS:

Autism spectrum disorders; Cell therapy; Inflammation; Major histocompatibility complex; Maternal immune activation; Mesenchymal stem cells

Conflict of interest statement

Conflict-of-interest statement: All authors have no conflicts of interest to report.

Publication type

Publication type

Supplemental Content

Full text links

Icon for Baishideng Publishing Group Inc. Icon for PubMed Central
Loading ...
Support Center